Rheonix, Inc. Announces Novel Microarray Production Technology to Support Multiplexed Endpoint Detection of Single Nucleotide Polymorphisms

Ithaca, NY – December 15, 2011 – Rheonix today announced that it has completed development of a novel microarray production technology to create a high-fidelity microarray, the Hy-Fi Microarray™. HyFi Microarrays provide simple, multiplexed end point detection for molecular assays and, in particular, a novel method to detect single nucleotide polymorphisms (SNPs) on the Rheonix CARD® system. While Rheonix intends to apply this proprietary microarray technology to improve SNP detection,… Read More »

Rheonix, Inc. Appoints Vice President of Operations and Quality Manager

Ithaca, NY – November 16, 2011 – Rheonix today announced the appointment of two individuals—Tom Karpen as Vice President of Operations overseeing engineering, production and quality teams and Terry Howell as Quality Manager. These two new members to the management team will be instrumental as the Company moves toward commercialization of its Rheonix CARD® system, a powerful automated microfluidic platform capable of analyzing raw clinical samples in a variety of… Read More »

Rheonix Announces New SeptiCARD Data Demonstrating Rapid Septicemia Diagnosis

Ithaca, NY – July 27, 2011 – Rheonix, Inc. today announced positive results in a new application of its powerful, automated, molecular diagnostic platform, termed SeptiCARD, for the detection of septicemia, the presence of bacteria in the blood often associated with severe infection. Results were presented in a poster session at the American Association for Clinical Chemistry (AACC) Annual Meeting held in Atlanta, Ga., July 24-28, 2011. These data continue… Read More »

Rheonix, Inc. to Present Data on Rheonix CARD® Technology at AACC Annual Meeting

Ithaca, NY – July 19, 2011 – Rheonix, Inc. today announced that data demonstrating the powerful, automated molecular diagnostic capabilities of the Rheonix CARD® system will be presented in a poster session at the American Association for Clinical Chemistry (AACC) Annual Meeting being held in Atlanta, GA, July 24-28, 2011. Rheonix will also exhibit at the Clinical Lab Expo, Booth #4434. “We now have a robust data set supporting our fully… Read More »

Mayo Clinic Announces Collaboration on Genotyping Test for Warfarin Sensitivity

ROCHESTER, Minn. — Mayo Clinic today announced that it has reached an agreement with Rheonix, Inc. to collaborate on the performance of a genotyping test for warfarin sensitivity in clinical and research settings. The genotyping test will be available for all patients of Mayo Clinic and is the subject of ongoing research for improved anticoagulation therapy. Additionally, the test will be offered through Mayo Clinic’s reference laboratory, Mayo Medical Laboratories,… Read More »

Rheonix Announces Patent Issuance and Allowance of Patent Applications for Its Molecular Diagnostic Platform

Ithaca, NY – June 2, 2011 – Rheonix, Inc., developer of the Rheonix CARD® system that provides a powerful microfluidic platform for the evolving molecular diagnostics industry, announced that on June 14, 2011 the U.S. Patent and Trademark Office will issue Patent Number 7,959,875, "Microfluidic Chips and Assay Systems‖ and on April 13, 2011 it allowed Patent Application Number 11/594,444, ―Microfluidic Systems‖ to the Company. These patents, together with existing… Read More »

Rheonix, Inc. to Present Powerful, Automated Molecular Diagnostic Capabilities at TIDES 2011

Ithaca, NY – May 18, 2011—Rheonix, Inc. today announced that Richard A. Montagna, Ph.D., Senior Vice President for Corporate Business Development and Scientific Affairs, will present at the TIDES: Oligonucleotide and Peptide Research, Technology and Product Development conference to be held May 22-25, 2011 in Boston. Dr. Montagna will present new data to support the diagnostic capabilities of Rheonix CARD® (Chemistry and Reagent Device) technology on Wednesday, May 25 at… Read More »

Rheonix Receives $500K SBIR Phase II Award from National Science Foundation to Complete Development of a Test for Contamination in Recreational Water

Ithaca, N.Y. — February 8, 2011 - Rheonix, Inc. today announced the receipt of a Small Business Innovation Research (SBIR) Phase II grant in the amount of $500,000 from the National Science Foundation (NSF) to continue development of a Rheonix CARD® (Chemistry and Reagent Device) system to detect certain types of water contamination. NSF awarded the grant based upon the progress made during the NSF-funded Phase I and IB program… Read More »
Rheonix receives FDA Emergency Use Authorization for Automated COVID-19 Test.
Learn More